Sugi Predict

Sugi Predict / Targets / UBA2

UBA2

SUMO-activating enzyme subunit 2 · Q9UBT2 · UBA2 on Sugi Atlas →

40,983 patent compounds predicted against UBA2, 30,793 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL150458 SCHEMBL150458 0.56 4/20
SCHEMBL175459 SCHEMBL175459 0.46 4/20
SCHEMBL155510 SCHEMBL155510 0.45 4/20
SCHEMBL155511 SCHEMBL155511 0.45 4/20
SCHEMBL46257 SCHEMBL46257 0.64 3/20
SCHEMBL191182 SCHEMBL191182 0.61 3/20
SCHEMBL46575 SCHEMBL46575 0.59 3/20
SCHEMBL191682 SCHEMBL191682 0.55 3/20
SCHEMBL364877 SCHEMBL364877 0.77 2/20
SCHEMBL364875 SCHEMBL364875 0.74 2/20
SCHEMBL195375 SCHEMBL195375 0.71 2/20
SCHEMBL364968 SCHEMBL364968 0.70 2/20
SCHEMBL365438 SCHEMBL365438 0.70 2/20
SCHEMBL365358 SCHEMBL365358 0.68 2/20
SCHEMBL364681 SCHEMBL364681 0.67 2/20
SCHEMBL364783 SCHEMBL364783 0.67 2/20
SCHEMBL365131 SCHEMBL365131 0.67 2/20
SCHEMBL364481 SCHEMBL364481 0.66 2/20
SCHEMBL365182 SCHEMBL365182 0.66 2/20
SCHEMBL364181 SCHEMBL364181 0.65 2/20

Clinical trials — most relevant to UBA2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
A Trial of Levodopa in Angelman Syndrome PHASE2/PHASE3COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Studying TAK-243 in Patients With Advanced Cancer PHASE1RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease EARLY_PHASE1RECRUITING
Glutamine Supplementation in People With Immune Dysregulation EARLY_PHASE1WITHDRAWN
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy nanCOMPLETED
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas nanRECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Establishment of a Prospective Clinical-biological Database nanRECRUITING
Identification of a New Gene Involved in Hereditary Lipodystrophy nanCOMPLETED
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED
Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria nanCOMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING
Targeting Oxidative Stress to Prevent Vascular and Skeletal Muscle Dysfunction During Disuse nanACTIVE_NOT_RECRUITING
Investigation of Copy Number Variations and Genetic Variants in POI nanRECRUITING
Autophagy Bladder Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a UBA2 binder may also engage these)

ProteinNameSimilarity
Q9Z1F9 — 1.000 Q9Z1F9 →
Q642Q1 — 1.000 Q642Q1 →
Q7ZY60 — 0.998 Q7ZY60 →
Q28GH3 — 0.995 Q28GH3 →
Q7SXG4 — 0.994 Q7SXG4 →
Q8C878 — 0.985 Q8C878 →
Q5R4A0 — 0.984 Q5R4A0 →
UBA3 NEDD8-activating enzyme E1 catalytic subunit 0.983 landscape →
Q99MI7 — 0.983 Q99MI7 →
Q7ZVX6 — 0.981 Q7ZVX6 →
Q5ZKY2 — 0.976 Q5ZKY2 →
A3KMV5 — 0.974 A3KMV5 →
Q641Y5 — 0.973 Q641Y5 →
Q5U300 — 0.973 Q5U300 →
Q02053 — 0.972 Q02053 →
UBA1 Ubiquitin-like modifier-activating enzyme 1 0.971 landscape →
E9Q4Z2 — 0.971 E9Q4Z2 →
Q6IQS6 — 0.971 Q6IQS6 →
Q29504 — 0.970 Q29504 →
ATG7 Ubiquitin-like modifier-activating enzyme ATG7 0.970 landscape →
Q4V7N2 — 0.970 Q4V7N2 →
A0A7U2QYM2 — 0.969 A0A7U2QYM2 →
Q9QW07 — 0.969 Q9QW07 →
ACACB Acetyl-CoA carboxylase 2 0.969 landscape →
Q9D906 — 0.968 Q9D906 →
Q6P4T2 — 0.967 Q6P4T2 →
Q7ZWS1 — 0.967 Q7ZWS1 →
Q9XGM2 — 0.967 Q9XGM2 →
Q7XQR9 — 0.967 Q7XQR9 →
Q07722 — 0.966 Q07722 →